Clincosm LogoSign in Get a demo

recurrent acute lymphoblastic leukemia

Showing 1 - 21 of 21
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia

Not yet recruiting
  • Recurrent Acute Leukemia of Ambiguous Lineage
  • +5 more
  • Biospecimen Collection
  • +12 more
  • (no location specified)
Mar 8, 2023

The Pediatric Acute Leukemia Screening Trial - A Study to Test

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +7 more
  • Biospecimen Collection
  • Birmingham, Alabama
  • +144 more
Jan 30, 2023

Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in

Suspended
  • Juvenile Myelomonocytic Leukemia
  • +27 more
  • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +7 more
  • Blinatumomab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic

Active, not recruiting
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 2, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid

Recruiting
  • Acute Lymphoblastic Leukemia in Remission
  • +11 more
  • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 24, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston

Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 6, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia

Recruiting
  • Acute Lymphoblastic Leukemia
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 29, 2022

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle

Terminated
Has Results
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +12 more
  • Laboratory Biomarker Analysis
  • ROR1 CAR-specific Autologous T-Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 11, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in

Completed
Has Results
  • Recurrent Acute Leukemia of Ambiguous Lineage
  • +5 more
  • Chemosensitivity Assay
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jun 29, 2022

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +5 more
  • Blinatumomab
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

Hematopoietic and Lymphoid Cell Tumor, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome Trial in Houston

Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +13 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 8, 2022

Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Allogeneic Hematopoietic Stem Cell

Completed
  • Acute Lymphoblastic Leukemia in Remission
  • +6 more
  • Allogeneic Bone Marrow Transplantation
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 15, 2021

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells,

Terminated
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +10 more
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Nov 17, 2021

Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Tumor, Recurrent Acute Lymphoblastic Leukemia Trial

Completed
  • Allogeneic Hematopoietic Stem Cell Transplant Recipient
  • +10 more
  • Ipilimumab
  • +2 more
  • Duarte, California
  • +12 more
Jun 23, 2021

CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Houston (Inotuzumab

Terminated
Has Results
  • CD22 Positive
  • +2 more
  • Inotuzumab Ozogamicin
  • Houston, Texas
    M D Anderson Cancer Center
Mar 17, 2021

B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia Trial in Seattle (Laboratory

Terminated
Has Results
  • B Acute Lymphoblastic Leukemia
  • +3 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 11, 2020

Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Tumor, Myelodysplastic/Myeloproliferative Tumor, Unclassifiable

Withdrawn
  • Acute Bilineal Leukemia
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 12, 2020